21 CFR 522.2065
§ 522.2065 Rabacfosadine.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 522.2065, § 522.2065 Rabacfosadine, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87528
- Permanent ID
ys:prov:87528@1- SHA-256
1b420cee07ace77cbf3d602033d59f8a2fbb7133191362b72d50c328348dd70c
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Specifications. Each vial of powder contains 16.4 milligrams (mg) rabacfosadine. Each milliliter of constituted solution contains 8.2 mg rabacfosadine.
(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.
(c) Conditions of use in dogs—(1) Amount. Administer rabacfosadine at 1 mg/kilogram body weight as a 30-minute intravenous infusion, once every 3 weeks, for up to 5 doses.
(2) Indications for use. For the treatment of lymphoma in dogs.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.